2017 Develop Pricing San Diego 
Xconomy
JANUARY 2, 2017
That being said, here’s what I’ll be keeping an eye on in Washington in 2017. When I worked in the Reagan Administration, the “Gipper” used to handle questions like this by saying he couldn’t respond to hypothetical questions. Overall, the bill will.
Xconomy
JANUARY 5, 2018
Hopefully a lot less hatred, greed, stupidity, and angst than 2017. Two other big questions we raised immediately became topics of conversation this week, thanks to Spark Therapeutics, which set the price for its gene therapy—the first ever approved in the U.S.—at We also covered gene therapy development news.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
APRIL 23, 2019
After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.
Xconomy
OCTOBER 28, 2016
Two “triple” combination regimens for CF , which are meant to expand the reach of its CF drugs, will begin Phase 2 trials by the end of the year, and two additional new CF drugs will start clinical testing in 2017. THIS WEEK IN DRUG PRICING…. —A coalition of investors pressed drug makers to justify price increases.
Xconomy
OCTOBER 7, 2016
The funding could be as much as $100 million, and the first grants will be announced in 2017. PRICE FIGHTS. With some caveats, ICER recommended lower prices. —Sarepta Pharmaceuticals (NASDAQ: SRPT ) struck a second deal in as many weeks to develop combination therapies for Duchenne muscular dystrophy.
socalTECH
NOVEMBER 19, 2018
San Diego-based uCast Global (www.ucastglobal.com), backed by Gary Winnick, is looking to tackle that entire area of content distribution, and is led by startup veteran Dr. Kanaan Jemili. We bought our first company in 2017 to create this, and we rolled up a few companies to bring this vision to life. I have a Ph.D.
Xconomy
NOVEMBER 11, 2016
Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. CRISPR DEVELOPMENTS. Now, the U.S. But Trump’s plans are unclear.
Expert insights. Personalized for you.
74 
Let's personalize your content